-
A Randomized, Placebo-controlled, Double-blind, Multi-center Phase 2/3 Trial To Assess Efficacy And Safety Of Octreotide Subcutaneous Depot (CAM2029) In Patients With Symptomatic Polycystic Liver Disease
Rochester, MN
The purpose of this trial is to evaluate the effectiveness and safety of 2 treatment regimens of CAM2029 versus placebo in patients with Polycystic Liver Disease (PLD).
-
A Study Of Polycystic Liver And Kidney Disease- Deployment Of Quality-of-life Tools To Practice
Rochester, MN
Statistical recording and characterization of a patient cohort with clinical or molecular diagnosis of polycystic liver or kidney disease (PLD/PKD). (2) Evaluation of patient reported outcomes in response to clinical interventions. Characterization of phenotypic severity, including liver volumes from available cross-sectional imaging (MRI/CT). Implementation of PLD-Q to evaluate the patient reported outcomes.
-
Cystic Kidney and Liver Disease Biobank
Rochester, MN
This research study is being done to create a collection of biospecimens (blood, urine, cyst fluid, bile, kidney or liver tissue, etc.) that can be used to facilitate the conduction of research on polycystic kidney and/or liver disease.
-
Foam Sclerotherapy for the Treatment of Symptomatic Kidney or Liver Cysts in Patients with Autosomal Dominant Polycystic Kidney and Liver Disease
Rochester, MN
The purpose of this study is to determine the impact of foam sclerotherapy of large, dominant kidney/liver cysts on quality of life outcomes and kidney/liver cyst volumes at up to 12 months of follow-up in patients with autosomal dominant polycystic kidney disease (ADPKD) and autosomal dominant polycystic liver disease (ADPLD).